Pink SheetPwC: Regulatory, Policy Uncertainty Constrain Dealmaking Life sciences deal volume and total valuation has been sluggish approaching the midpoint of 2025, even compared to the below-average numbers p
ScripWoodcock: Don’t Do The Wrong Study, Even If FDA Tells You To Janet Woodcock said she has told drug developers not to blindly follow agency advice, an unusual comment from a former US Food and Drug Adm
ScripEli Lilly and Verve Therapeutics agreed to a buyout on June 17 valued at approximately $1bn with a contingent value right (CVR) that could be attainable, bringing the total deal value to around $1.3bn
Generics BulletinAmgen is trying to gain traction for its Pavblu (aflibercept-ayyh) biosimilar purely by offering better financial incentives, according to Eylea (aflibercept) originator Regeneron, which is continuing